The University of Tokyo · 의학
히라쿠 쿠마마루 교수의 연구실은 주로 의료정보학과 약물이용연구를 기반으로 한 임상 및 약리 epidemiology 연구를 중심으로 활동하고 있습니다. 특히 메디케어 및 일본의 임상기반 데이터베이스를 활용해 뇌졸중, 경동맥우회술, 노인의 취약성 평가 등 다양한 임상적 결과를 정량적으로 분석하고 있으며, 데이터 기반의 정책 및 치료 효과 평가에 기여하고 있습니다. 고도의 통계적 모델링과 데이터 기반의 결과 추정 기법을 응용해 임상 연구의 정확성과 신뢰성을 높이는 데 초점을 맞추고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Claims-based algorithms to identify stroke in a contemporary Medicare cohort had high positive predictive value and specificity, supporting their use as outcomes for etiologic and comparative effectiveness studies in similar populations. These inpatient algorithms are unsuitable for estimating stroke incidence because of low sensitivity.
The rate of CEA procedures decreased substantially during 2001 to 2008, as did surgeon past-year case-volume. The postprocedural mortality in Medicare beneficiaries was high compared with trial patients but somewhat improved over time. Those operated by lower past-year case-volume surgeons had increased mortality.
This study was funded by the Patient-Centered Outcomes Research Institute (ME-1309-06274). Kumamaru, Kohsaka, and Miyata are affiliated with the Department of Healthcare Quality Assessment at the University of Tokyo, which is a social collaboration department supported by National Clinical Database. The department was formerly supported by endowments from Johnson & Johnson K.K., Nipro, Teijin Pharma, Kaketsuken K.K., St. Jude Medical Japan, Novartis Pharma K.K., Taiho Pharmaceutical, W. L. Gore
The frailty algorithms were applicable to the Japanese system and could contribute to the identifications of enrollees at risk of long-term mortality or LTC use.
The number of databases available for clinico and pharmacoepidemiological research and the proportion of the population they cover are increasing in Japan. The differences in their characteristics mean that the appropriate database must be selected for a particular study purpose.
hdDRSs using historical data with dimension reduction and shrinkage was feasible, and improved confounding adjustment in two studies of newly marketed medications.
